BRAF-V600E–mutated Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis with response to BRAF inhibitor

著者: Rosemarie Mastropolo, Allison Close, S. W. Allen, Kenneth L. McClain, Scott H. Maurer, Jennifer Picarsic - Blood Advances 2019 被引用: 42

Key Points Demonstration of BRAF-V600E in Rosai-Dorfman-Destombes disease requires sensitive molecular assays and molecular-based tissue immunostain. BRAF-V600E blood testing is important for disease-monitoring BRAF-mutated histiocytosis and can guide inhibitor treatment plans.